Kenvue

Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Inc. (NYSE: KVUE)—the consumer health company behind brands such as Tylenol, Band-Aid, Listerine, Neutrogena, and Aveeno—is trading in a market that feels less like “buy-and-hold fundamentals” and more like “event-driven probability.” The reason: Kimberly-Clark’s planned acquisition of Kenvue, a

15 December 2025

Kenvue (KVUE) Stock Today: Dividend Payout, Insider Buying and Kimberly-Clark Deal in Focus – November 26, 2025

Kenvue Inc. (NYSE: KVUE) — the Johnson & Johnson consumer-health spin‑off behind Tylenol, Listerine and Neutrogena — is back in the spotlight on Wednesday, November 26, 2025, as the stock trades higher on dividend payday, fresh insider and hedge‑fund buying

26 November 2025

Business News · Dividends · Insider Trading · Investment Analysis · NYSE:KMB · NYSE:KVUE · Stock Market

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Company Overview & History Kenvue Inc. is a leading consumer health company formed from Johnson & Johnson’s storied consumer products division. The name “Kenvue” combines “ken” (knowledge) and “vue” (view), reflecting a vision of insight-driven care en.wikipedia.org. As a spin-off,

4 November 2025

Financial Analysis · Investment Strategies · Mergers & Acquisitions · NYSE:JNJ · NYSE:KMB · NYSE:KVUE · Pharmaceutical Industry · Stock Market News

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Stock Price and Intraday Performance (Nov 3, 2025) Kenvue’s stock soared on the buyout news, delivering a sharp one-day gain. As of midday Nov. 3, KVUE traded around $17–$18, up roughly 18–20% intraday reuters.com. Prior to the announcement, the stock

3 November 2025

Earnings Reports · Financial News · Investing · Mergers & Acquisitions · NYSE:KMB · NYSE:KVUE · Stock Market

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Stock Hits a 52-Week Low on Legal Woes Kenvue’s shares collapsed to an all-time low since their mid-2023 IPO, closing around $14 after Thursday’s 13.2% plunge stocktwits.com. The one-day drop – Kenvue’s worst on record – was triggered by headline

17 October 2025

Financial Analysis · Health News · Lawsuits · NYSE:KVUE · Pharmaceutical Industry · Stock Market

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Recent Market Moves Kenvue’s stock (NYSE: KVUE) has been volatile. On Oct 16, 2025 it closed around $15.46, marking a fresh 52-week low investing.com. Over the prior week the shares had slid ~13%, partly driven by jitters over UK talc

16 October 2025

Health Industry · Investment News · Market Analysis · NYSE:KVUE · Pharmaceutical Companies · Stock Market